Company Overview

Sonoma Pharmaceuticals, Inc. is a publicly traded specialty pharmaceutical and medical technology company focused on the development, manufacture, and commercialization of stabilized hypochlorous acid–based solutions for dermatological, wound care, eye care, and related medical applications. The company operates within the pharmaceuticals, medical devices, and dermatology and wound care industries, with products positioned as prescription and over-the-counter therapies that support infection management, inflammation reduction, and healing. Its core revenue drivers are topical therapeutic products marketed under proprietary brands and licensed to distributors in international markets.

The company’s primary customers include dermatologists, wound care specialists, hospitals, clinics, and retail pharmacies, as well as international distribution partners. Sonoma Pharmaceuticals’ strategic positioning is based on its proprietary Microcyn technology platform, which produces stabilized hypochlorous acid formulations designed to be non-toxic to human tissue while maintaining antimicrobial properties. The company was founded in 2005 as Oculus Innovative Sciences, Inc., later rebranding to Sonoma Pharmaceuticals, Inc. in 2016 to reflect a broader dermatology and therapeutics focus and a transition toward consumer-facing branded products alongside professional medical use.

Business Operations

Sonoma Pharmaceuticals generates revenue through the sale and licensing of products across several core business segments, including Dermatology, Wound Care, Eye Care, Animal Health, and Dental applications. Its product portfolio includes branded solutions such as Microcyn, Levicyn, Cellese, and related formulations, which are sold directly in certain markets and distributed through third-party partners in others. Revenue is derived from product sales, licensing agreements, and distribution arrangements, with international markets representing a significant portion of total sales.

The company conducts manufacturing and product development internally while leveraging a network of global distributors and subsidiaries, including Sonoma Pharmaceuticals International, Inc., to expand market reach. Operations span both domestic and international markets, with regulatory approvals varying by jurisdiction. Sonoma controls its core intellectual property related to hypochlorous acid stabilization technology and relies on a combination of direct sales efforts and strategic partnerships rather than large-scale joint ventures. No material joint ventures have been consistently identified in public disclosures; data inconclusive based on available public sources.

Strategic Position & Investments

Sonoma Pharmaceuticals’ strategic direction emphasizes expanding its dermatology-focused product portfolio, increasing penetration in international markets, and leveraging its proprietary technology platform across new therapeutic indications. Growth initiatives include the introduction of new branded dermatology products, expansion into consumer skincare categories in select regions, and regulatory approvals for additional medical indications. The company has also focused on cost containment and operational efficiency to support its transition toward sustainable profitability.

Historically, growth has been driven more by organic product development and regional licensing arrangements than by large-scale acquisitions. The company maintains several wholly owned subsidiaries to manage international operations but has not disclosed significant recent acquisitions of independent operating companies. Emerging areas of interest include broader consumer dermatology and skin health applications derived from its core technology, though commercialization timelines and revenue impact remain uncertain based on public information.

Geographic Footprint

Sonoma Pharmaceuticals is headquartered in North America, with its corporate headquarters located in the United States. The company maintains a significant international presence, with product sales and distribution across Europe, Latin America, Asia-Pacific, and parts of the Middle East. International markets contribute a substantial share of revenue, supported by regional subsidiaries and long-term distribution agreements.

Operational influence outside the United States is primarily achieved through regulatory approvals and localized branding strategies tailored to regional medical and consumer markets. The company’s international footprint is characterized by broad geographic reach rather than deep operational infrastructure in each country, relying instead on partnerships and distributors to scale market access efficiently across multiple continents.

Leadership & Governance

Sonoma Pharmaceuticals was founded by Scott Harter and Jon Block, who played key roles in developing the company’s core technology and early commercialization strategy. The current leadership team is focused on disciplined execution, international growth, and leveraging science-driven product differentiation within dermatology and wound care markets. The company’s governance structure includes an independent board of directors overseeing strategic direction and regulatory compliance.

Key executives include:

• Amy Trombly – President and Chief Executive Officer
• Kevin Tang – Chief Financial Officer
• David J. Gill – Chief Operating Officer
• Michael McShane – Vice President, Sales and Marketing

Leadership philosophy, as reflected in public disclosures, emphasizes clinically validated innovation, regulatory compliance, and capital-efficient growth. While management has articulated a long-term vision centered on expanding dermatology and skin health applications, specific forward-looking performance outcomes remain subject to market conditions and are not guaranteed based on available public sources.